IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of $27.67 million. The enterprise value is $26.68 million.

Market Cap	27.67M
Enterprise Value	26.68M

Important Dates

The last earnings date was Monday, November 17, 2025, before market open.

Earnings Date	Nov 17, 2025
Ex-Dividend Date	n/a

Share Statistics

IGC Pharma has 92.87 million shares outstanding. The number of shares has increased by 19.49% in one year.

Current Share Class	92.87M
Shares Outstanding	92.87M
Shares Change (YoY)	+19.49%
Shares Change (QoQ)	+8.95%
Owned by Insiders (%)	8.11%
Owned by Institutions (%)	20.74%
Float	85.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.27
Forward PS	n/a
PB Ratio	3.39
P/TBV Ratio	8.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	24.12
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.02.

Current Ratio	1.32
Quick Ratio	0.79
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -83.34% and return on invested capital (ROIC) is -63.56%.

Return on Equity (ROE)	-83.34%
Return on Assets (ROA)	-50.31%
Return on Invested Capital (ROIC)	-63.56%
Return on Capital Employed (ROCE)	-98.37%
Revenue Per Employee	$15,800
Profits Per Employee	-$92,086
Employee Count	70
Asset Turnover	0.11
Inventory Turnover	0.55

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.11% in the last 52 weeks. The beta is 0.25, so IGC Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.25
52-Week Price Change	-17.11%
50-Day Moving Average	0.37
200-Day Moving Average	0.34
Relative Strength Index (RSI)	26.54
Average Volume (20 Days)	465,540

Short Selling Information

The latest short interest is 244,156, so 0.26% of the outstanding shares have been sold short.

Short Interest	244,156
Short Previous Month	278,841
Short % of Shares Out	0.26%
Short % of Float	0.29%
Short Ratio (days to cover)	0.27

Income Statement

In the last 12 months, IGC Pharma had revenue of $1.11 million and -$6.45 million in losses. Loss per share was -$0.08.

Revenue	1.11M
Gross Profit	511,000
Operating Income	-8.10M
Pretax Income	-6.45M
Net Income	-6.45M
EBITDA	-7.52M
EBIT	-8.10M
Loss Per Share	-$0.08

Full Income Statement

Balance Sheet

The company has $1.13 million in cash and $146,000 in debt, giving a net cash position of $984,000 or $0.01 per share.

Cash & Cash Equivalents	1.13M
Total Debt	146,000
Net Cash	984,000
Net Cash Per Share	$0.01
Equity (Book Value)	8.09M
Book Value Per Share	0.09
Working Capital	490,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$5.54 million and capital expenditures -$82,000, giving a free cash flow of -$5.63 million.

Operating Cash Flow	-5.54M
Capital Expenditures	-82,000
Free Cash Flow	-5.63M
FCF Per Share	-$0.06

Full Cash Flow Statement

Margins

Gross Margin	46.20%
Operating Margin	-731.92%
Pretax Margin	-582.82%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.49%
Shareholder Yield	-19.49%
Earnings Yield	-23.30%
FCF Yield	-20.34%

Analyst Forecast

The average price target for IGC Pharma is $4.00, which is 1,242.73% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.00
Price Target Difference	1,242.73%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 1:10.

Last Split Date	Apr 19, 2013
Split Type	Reverse
Split Ratio	1:10

Scores

IGC Pharma has an Altman Z-Score of -10.12 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.12
Piotroski F-Score	3